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Abstract
Background: The novel oral antibiotic formulation Rifamycin SV-MMX
®
, with a targeted delivery to the distal small
bowel and colon, was superior to placebo in treating travellers’ diarrhea (TD) in a previous study. Thus, a study
was designed to compare this poorly absorbed antibiotic with the systemic agent ciprofloxacin.
Methods: In a randomized double-blind phase 3 study (ERASE), the efficacy and safety of Rifamycin SV-MMX®
400mg twice daily (RIF-MMX) was compared with ciprofloxacin 500mg twice daily in the oral treatment of TD.
Overall, 835 international visitors to India, Guatemala or Ecuador with acute TD were randomized to receive a 3-day
treatment with RIF-MMX (n = 420) or ciprofloxacin (n = 415). Primary endpoint was time to last unformed stool
(TLUS), after which clinical cure was declared. Stools samples for microbiological evaluation were collected at the
baseline visit and the end of treatment visit.
Results: Median TLUS in the RIF-MMX group was 42.8 h versus 36.8 h in the ciprofloxacin group indicating non-
inferiority of RIF-MMX to ciprofloxacin (P = 0.0035). Secondary efficacy endpoint results including clinical cure rate,
treatment failure rate, requirement of rescue therapy as well as microbiological eradication rate confirmed those of
the primary analysis indicating equal efficacy for both compounds. While patients receiving ciprofloxacin showed a
significant increase of Extended Spectrum Beta Lactamase Producing—Escherichia coli (ESBL-E. Coli) colonization
rates after 3-days treatment (6.9%), rates did not increase in patients receiving RIF-MMX (−0.3%). Both drugs were
well-tolerated and safe.
Conclusion: The novel multi-matrix formulation of the broad-spectrum, poorly absorbed antibiotic Rifamycin SV
was found non-inferior to the systemic antibiotic ciprofloxacin in the oral treatment of non-dysenteric TD with the
advantage of a lower risk of ESBL-E. Coli acquisition.
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Introduction
Travellers’ diarrhea (TD) remains the most common health
problem experienced by travellers in lower income regions of
the world.1 Depending on the destination, up to 30% of
travellers develop TD within the first 2 weeks abroad.2,3 TD is
often accompanied by other symptoms, such as abdominal
cramps, faecal urgency, nausea, vomiting, and, if the pathogen
has been invasive, by fever and blood in the stools. The most
© International Society of Travel Medicine, 2018. Published by Oxford University Press.
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common agents isolated from patients with TD are enteric
diarrhea-producing E. coli (DEC), especially enterotoxigenic E.
coli (ETEC) and enteroaggregative E. coli (EAEC). Other causes
are mucosa-invasive bacteria including Campylobacter jejuni,
Shigella spp. and Salmonella spp. At least, 80% of TD cases are
of bacterial origin and noroviruses and protozoan parasites
such as Giardia lamblia and Cryptosporidium play a minor
role. Presence of more than one pathogen is common.1,4,5
Antimotility (mainly loperamide) and antimicrobial drugs, so
far mainly fluoroquinolones and azithromycin, are the main
therapeutic options for TD.6,7 Increased anti-bacterial resistance
to fluoroquinolones,8 the detection of extended spectrum β-lac-
tamase-producing E. coli (ESBL-E. coli) strains with subsequent
risk of transmission,9,10 and concern for tendon, nervous sys-
tem, ocular and vascular complications11–14 have recently
resulted in restricted recommendations for the use of fluoroqui-
nolones in TD patients. In contrast, orally administered poorly
absorbable antibiotics such as rifaximin have been suggested for
therapy of TD,15 as they act in the lumen of in the gastrointes-
tinal tract and thus have a low-toxicity profile. Rifaximin is
widely approved in the treatment of TD caused by non-invasive
bacterial pathogen strains.16
Closely related to rifaximin, rifamycin SV is an oral poorly
absorbable, broadspectrum antibiotic belonging to the class of ansa-
mycins.17 Rifamycin SV-MMX
®
(RIF-MMX) tablets contain the
active ingredient rifamycin SV at a concentration of 200mg/tablet.
The new oral formulation18 starts to release active compound only
after reaching intestinal pH-levels of pH ≥ 7 with an additional 1-h
delay upon reaching this pH, thereby targeting the distal small
bowel and colon where pH-levels are ≥7. The anti-bacterial activity
of rifamycin sodium against the most frequent microorganisms
causing TD as well as Clostridium difficile has been demonstrated.19
In humans, Rifamycin SV <1% of the administered dose is
absorbed after oral administration of RIF-MMX.20
RIF-MMX proved to be superior over placebo by shortening
the duration of TD in patients with a broad range of patho-
gens.21 In addition, the unique pharmacokinetic properties of
the drug offer evidence that TD pathogens worked at the level
of the distal small bowel and colon.21 Thus, it was decided to
design a second pivotal study and to compare the efficacy and
safety of RIF-MMX with ciprofloxacin for treatment of TD.
Methods
Study design
A randomized, double-blind, double-dummy, multi-center, com-
parative 4/5-day non-inferiority phase III clinical trial (Evaluation
of Rifamycin as a topically acting Antibiotic for Safety and
Efficacy in travellers’ diarrhea (ERASE)) was conducted between
23 November 2010 and 15 February 2016, in 17 study centers in
India and 2 centers in Latin America (Ecuador, Guatemala). The
study design was based on two arms in the form of a parallel
group comparison with the goal to assess efficacy and safety of a
3-day, twice daily, oral treatment with Rifamycin SV-MMX
®
ver-
sus ciprofloxacin in TD patients.
The study was conducted in accordance with good clinical
practice, the Declaration of Helsinki, all applicable national laws
and regulations, and it was approved by independent ethics com-
mittees at each of the centers prior to starting recruitment. All
patients gave written informed consent prior to participating.
This study is registered with ClinicalTrials.gov (NCT01208922).
Population
Men and women aged at least 18 years who arrived within the
past 4 weeks from an industrialized country were eligible if they
had acute moderate to severe TD, defined as at least three
unformed, watery or soft stools accompanied by symptoms
within 24 h preceding randomization with duration of illness
≤72 h. Presence of one or more signs or symptoms of enteric
infection (gas/flatulence, nausea, vomiting, abdominal cramps
or pain, rectal tenesmus, faecal urgency) of moderate to severe
intensity was mandatory. Symptoms were considered moderate
if they interfered with planned activities and as severe if they
completely prevented planned activities.
Excluded were patients who were residents of any country
with high incidence rates of diarrhea within the past 6 months,
or at the time of presentation diarrhea of >72 h duration, fever
(>38.0°C), passage of grossly bloody stools, known or sus-
pected infection with a non-bacterial pathogen (e.g. HIV or viral
hepatitis), moderate or severe dehydration, history of inflamma-
tory bowel disease or celiac disease. In addition, patients were
excluded if they had taken more than two doses of an anti-
diarrheal medication within 24 h or received an antibiotic
within 7 days prior to randomization. The use of these medica-
tions during the study was also prohibited.
Randomization and procedures
Eligible patients were randomized in a 1:1 ratio to receive either
two Rifamycin SV-MMX
®
200-mg tablets twice daily or one
ciprofloxacin 500-mg capsule twice daily for 3 days. The study
drugs were administered orally at breakfast and dinnertime. For
allocation of patients, a computer-generated list of random
numbers was prepared using a block size of four. Randomization
was concealed by packaging the study medication using the
double-dummy technique to guarantee blinding for all patients,
investigators and any other persons involved in the conduct of the
study. The study medication was consecutively numbered for each
patient according to the randomization schedule, and investigators
dispensed the study medication as per the randomization schedule.
Patients recorded for 5 days the precise time of each drug adminis-
tration in their diaries, time and consistency of each stool (watery,
soft, formed), detailed quantitative information of gastrointestinal
symptoms (abdominal pain/cramps, intensity of gas/flatulence, ten-
esmus, faecal urgency, nausea, vomiting), any AE occurring in
between visits or any intake of concomitant medication. Safety
and efficacy were assessed at Visit 2 (Day 2), Visit 3 (Day 4 or 5)
and the final visit (Day 6). Stool samples were collected before
treatment (Visit 1), and on the day after the last dose of trial drug
(Visit 3) and sent to a central laboratory for blinded pathogen
identification and antibiotic susceptibility testing (University of
Texas, USA). If a patient received rescue therapy within the 120-h
after ingestion of the first dose of the study drug, the patient was
considered a treatment failure.
Study endpoints
The study was designed to prove non-inferiority of Rifamycin
SV-MMX
®
to ciprofloxacin in terms of time from first dose of
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study drug to the last unformed stool. The primary endpoint time
to last unformed stool (TLUS) was defined as the interval in hours
between the first dose of study drug and the last unformed stool
passed, after which clinical cure was declared, i.e. time between the
first dose of study medication and the last unformed stool before
the end of the clinical cure period. TLUS was also calculated using
the last unformed stool before the start of the first clinical cure per-
iod (modified TLUS). Patients receiving rescue therapy, patients
who terminated the study early due to lack of efficacy, or patients
who terminated the study without clinical cure were considered to
have a TLUS of 120 h.
Secondary efficacy endpoints included clinical cure rate (24-h
period with no clinical symptoms except mild flatulence, no fever,
no watery stools and no more than two soft stools OR 48-h peri-
od with no stools or only formed stools, and no fever, with or
without symptoms of enteric infection), improvement (≥50%
reduction in the number of unformed stools passing during a 24-
h period compared with number of stools passed during 24 h
before first intake of study medication), treatment failure rate
(clinical deterioration after ≥24 h of study treatment or illness
continuing 120 h after start of study treatment or use of anti-
microbial prohibited concomitant medication), modified TLUS
(the time (h) between the first dose of the study drug and the last
unformed stool before the start of the clinical cure period), num-
ber of unformed stools passed, gastrointestinal symptoms,
requirement of rescue therapy, minimum inhibitory concentration
(MIC50 and MIC90), microbiological eradication rate (pathogen
eradication in post-treatment stool). The frequency of adverse
events (AEs), clinically relevant changes in any laboratory para-
meters, vital signs and physical examination were assessed.
Microbiological analyses
For analysis purposes, the following groups of pathogens were
defined:
– Diarrheagenic E. coli group: positive for at least one of the follow-
ing tests: enterotoxigenic E. coli (heat stable toxin, heat labile toxin
or heat stable/heat labile toxin) or enteroaggregative E. coli without
any positive result for pathogens of the potentially invasive/non-bac-
terial group.
– Potentially invasive/non-bacterial group: positive for at least one
of the following pathogens: Giardia lamblia, Cryptosporidium par-
vum, Entamoeba histolytica, Shigella spp., Salmonella spp.,
Campylobacter jejuni, Aeromonas spp., Plesiomonas spp., Vibrio
spp. or Norovirus.
– Pathogen-negative illness group: no positive pathogen identifica-
tion at baseline.
To analyse the primary endpoint TLUS in more detail, we
further split the potentially invasive/non-bacterial group in the
following subgroups:
– Potentially invasive bacteria group: positive for at least one of the
following pathogens: Shigella spp., Salmonella spp., Campylobacter
jejuni, Aeromonas spp., Plesiomonas spp. or Vibrio spp. and nega-
tive for DEC, protozoa and norovirus.
– Protozoa group: positive for at least one of the following patho-
gens: Giardia lamblia, Cryptosporidium parvum or Entamoeba his-
tolytica and negative for DEC, potentially invasive bacteria and
norovirus.
– Norovirus group: positive for norovirus and negative for DEC,
potentially invasive bacteria, protozoa and norovirus.
The presence of enteropathogens in stool samples was evaluated
using published methods.22–24 In short, the stools blinded as to
treatment group were shipped on dry ice to the central labora-
tory at Houston/USA. Colonies from each stool culture were
screened for enterotoxigenic E. coli (ETEC) by showing that the
organism produced heat-labile enterotoxin (LT) and/or heat-
stable enterotoxin (ST) by DNA hybridization and for the pres-
ence of enteroaggregative E. coli (EAEC) by a HEp-2 assay.
Shigella species, Salmonella species, Vibrio species, Campylobacter
jejuni, Aeromonas species and Plesiomonas species were analyzed
using six standard media: MacConkey, Tergitol, Hektoen enteric,
Yersinia, TCBS and Campylobacter agar plates. Stools were exam-
ined for enteric protozoal parasites, including Giardia lamblia,
Cryptosporidium spp. and Entamoeba histolytica, by use of
ELISAs. Norovirus was detected by RT-PCR. The MICs of the fol-
lowing antibiotics were evaluated: ciprofloxacin (Sigma-Aldrich,
St. Louis, MO, USA), rifamycin SV (MP biomedical, Solon, OH,
USA) and rifaximin (Sigma-Aldrich). The MICs were determined
by the agar dilution method as standardized by the Clinical and
Laboratory Standards Institute.25 For quality control of antimicro-
bial potency, the MICs of the recommended control strains (E. coli
ATCC 25922, Staphylococcus aureus ATCC 29213, Pseudomonas
aeruginosa ATCC 27853 and Enterococcus faecalis ATCC 29212)
were determined with the test strains for each antimicrobial agent
and the MICs were within published ranges. To look for extended
spectrum beta lactamase (ESBL) resistance of E. coli strains, the
stools blinded as to treatment group were stored at −80°C before
analysis. The stools were thawed and plated directly onto three
MacConkey agar plates with ceftazidime (1 μg/ml), ceftriaxone
(1 μg/ml) or cefotaxime (1 μg/ml) and incubated at 37°C for 24 h.
E. coli-like colonies growing were tested for synergistic resistance
profile in Mueller–Hinton agar using ceftazidime (30 μg), clavula-
nate–amoxicillin (10 μg) and cefotaxime (10 μg) disks using pub-
lished methods.25,26 Quality control stains Klebsiella pneumoniae
ATCC 700603 and E. coli ATCC 25922 were included in the
study. E. coli was recovered in 91% of the frozen stool samples
and, thus the freezing step is unlikely to affect the analysis.
Sample size and statistical analysis
The sample size calculation was based on the primary efficacy
variable TLUS. The median TLUS for ciprofloxacin patients
was assumed as 27.5 h and 28.85 h for RIF-MMX patients.
Assuming an exclusion rate of 10% from the per protocol popu-
lation, 388 patients had to be included in each treatment group
to attain a target power of 80%. The study protocol pre-
specified a three-stage group-sequential adaptive design with
possible sample size adjustment or early stopping of the study
for efficacy, futility or safety after the interim analysis. The
interim analyses were planned to be performed at 50% and
75% of the initially planned sample size. Interim analyses were
conducted by an independent data monitoring committee
(IDMC) established by the sponsor prior to the interim analysis.
Upon recommendation of the IDMC after second interim ana-
lysis, the total sample size was increased to up to 1032 patients.
This is based on the fact that the observed response rates were
different from the originally expected rates. Therefore, in this
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adaptive group sequential design, the revised sample size was
needed to show a significant non-inferiority with a power of
80% at the end of the study within the pre-specified, tight non-
inferiority margin. The confirmatory non-inferiority test of the
primary efficacy variable was performed for the per-protocol
(PP) analysis set with a sensitivity test for the ITT population.
The non-inferiority margin acceptable was defined by a max-
imally acceptable difference in the median TLUS of 8.5 h (and
corresponding delta = 0.764 for the hazard ratio) between
Rifamycin SV-MMX® and the reference drug ciprofloxacin.
Patients with lack of compliance, intake of forbidden concomi-
tant medication, violation of eligibility criteria or early discon-
tinuation due to AEs without causal relationship with study
drug, were excluded from the PP population. Safety analyses
were performed for the safety population. Statistical testing of
the primary endpoint was done via the ADDPLAN system. All
other analyses were conducted using the SAS statistical package
for Windows (SAS Institute, Cary, NC).
Results
Patients
In total, 835 patients were randomized and treated with study
medication and thus, comprised both the safety and ITT popula-
tion; 420 patients received RIF-MMX and 415 patients cipro-
floxacin (Fig. 1). The population included 805 patients in India
(96.4%; 405 RIF-MMX, 400 ciprofloxacin) and 30 patients in
Latin America (3.5%; 15 in each group). The study was com-
pleted by 814 patients (97.5%); the most frequent reason for
premature termination was lack of patient’s co-operation, fol-
lowed by lack of efficacy and intolerable adverse events (AEs)
(Fig. 1 A). The respective proportions were similar in both treat-
ment groups. As 68 (8.1%) patients had to be excluded from
the PP population (36 RIF-MMX, 32 ciprofloxacin), the result-
ing PP population consisted of 767 patients (91.9%; 384 RIF-
MMX, 383 ciprofloxacin). The most frequent reasons for
exclusion included lack of compliance, use of prohibited medi-
cation and violation of inclusion/exclusion criteria (Fig. 1B).
Demographics including type of traveller, country of resi-
dence and disease-specific history did not differ between treat-
ment groups (Table 1). Most patients suffered from moderate
(78.7%), a smaller proportion from severe TD (21.2%). The
presence of at least one pathogen at baseline was similar in both
treatment groups with an overall rate of 62.3% in the ITT
population; multiple pathogens were identified in 23.7% of the
patients. The Diarrheagenic E. coli (DEC) group comprised
38.0% of the patients with ETEC/ST (33.5%) and EAEC
(25.1%) as the most frequent microorganisms, whereas poten-
tially invasive/non-bacterial pathogens were isolated in 24.3%
of the patients (Table 2). In 37.1% of the patients, no pathogen
could be isolated.
Efficacy
In the PP analysis, median TLUS was 42.8 h (IQR [21.3, 66.5])
in the RIF-MMX group as compared with 36.8 h (IQR [20.4,
65.5]) in the ciprofloxacin group. This indicated non-inferiority
of RIF-MMX to ciprofloxacin (P = 0.0035) (Table 3A; Fig. 2).
Results from the ITT analysis confirmed the PP analysis: median
TLUS in the RIF-MMX group was 44.3 h (IQR [21.5, 68.2]) vs.
40.3 h (95% CI [20.5, 67.0]) in the ciprofloxacin group with
P = 0.0011 for non-inferiority in the ITT population.
Subgroup analyses of the median TLUS by region and dur-
ation of disease symptoms prior to treatment did not reveal any
significant differences between the two treatments (Table 3B).
However, TD patients positive for potentially invasive bacteria
had a statistically significant shorter TLUS in ciprofloxacin
group compared with RIF-MMX group (Table 3B). All other
comparisons in relation to pathogen status did not reveal any
significant differences between the two treatment groups. In
addition, subgroup analysis revealed that in both treatment
groups, the median TLUS was the longer the later the treatment
was started after the onset of symptoms (Table 3B). While this
Figure 1. Disposition of patients.
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effect was independent of the treatment arm, using a cox regres-
sion model we found that patients with a treatment start 0–24 h
after onset of symptoms had a shorter TLUS than patients with a
disease duration prior of treatment of 24–<48 h (hazard ratio
(HR): 0.475; 95% CI: 0.401, 0.563; P < 0.0001) or 48–<72 h
(HR: 0.355; 95% CI: 0.278, 0.453; P < 0.0001). Subgroup ana-
lysis of the median TLUS by patients with and without presence of
blood and/or mucus in the macroscopic stool analysis did also not
reveal any statistical difference (Table 3B). No difference in the
median modified TLUS between the RIF-MMX group (32.3 h;
95% CI [28.7, 39.4]) and the ciprofloxacin group (31.0 h; 95%
CI: 28.5, 34.0) emerged (Log Rank test: P = 0.7047; PP analysis).
The analysis of the secondary endpoints clinical cure rate,
treatment failure rate and requirement of rescue therapy revealed
similar results in both treatment groups with no statistically signifi-
cant difference (Table 3C). Furthermore, both treatments not only
rapidly reduced the number of unformed stools in a similar man-
ner, but also resolved the gastrointestinal symptoms of the enteric
infection (Fig. 3).
Microbiological eradication rate and MICs
Independent of the pathogen species, the pathogens identified at
baseline could be eradicated in around half of the patients in
both treatment groups (Table 4). Similarly, no difference in
terms of the microbiological eradication rates by isolate was
found. MICs were determined for all pathogens and both treat-
ment groups as well as for pre- and post-treatment (Table 5).
For the DEC group, increases of MIC50 and MIC90 between
pre- and post-treatment became apparent in the RIF-MMX
group for Rifamycin and rifaximin (data not shown), but not
for ciprofloxacin. In the ciprofloxacin group, increases of
MIC50 and MIC90 became apparent for ciprofloxacin, but not
for Rifamycin SV. For the potentially invasive and non-bacterial
pathogens, the numbers of available microbiological samples
after treatment were too small to provide results of sufficient
robustness.
ESBL-E. coli colonization
A post-hoc analysis of ESBL-E. coli colonization at baseline and
after treatment was performed in both treatment groups. Of
note, patients positive for ESBL-E. coli at baseline were only
found at sites in India (103/662), whereas none of the tested
patients from Latin America was positive (0/21). At baseline,
both treatment groups had similar ESBL-E. coli colonization
rates (Table 6). Interestingly, ESBL-E. coli rates did not rise after
3 days of RIF-MMX treatment. In contrast, patients rando-
mized to ciprofloxacin showed a significant increase at the end
of the 3-days treatment period (Table 6). Furthermore, among
patients ESBL-E. coli negative at enrolment, a significantly high-
er number of patients receiving ciprofloxacin newly acquired
ESBL-E. coli compared with those in the RIF-MMX group,
resulting in an odds ratio of 1.84 (Table 6).
Safety
The incidence of AEs and adverse drug reactions (ADRs) was
similar in both treatment groups. In total, 124/835 patients
(14.9%) experienced AEs (RIF-MMX: 14.8%; ciprofloxacin:
14.9%). ADRs were reported by 34/420 patients (8.1%) in the
RIF-MMX group and by 31/415 (7.5%) patients in the cipro-
floxacin group. One patient in the RIF-MMX group withdrew
the study drug after 1 day of treatment due to the intolerable
AE ‘worsening of diarrhea’, that was considered non-serious
and was of moderate intensity. The relationship to the study
drug was considered unlikely and the patient recovered. No ser-
ious AE or death was reported. No further safety concerns arose
from the results for vital signs, laboratory and physical exami-
nations, and no meaningful differences between the treatment
groups became obvious.
Table 1. Demographic and TD characteristics (ITT population)
Rifamycin
SV-MMX
®
Ciprofloxacin
(N = 420) (N = 415)
Sex, n (%)
Male 205 (48.8) 218 (52.5)
Female 215 (51.2) 197 (47.5)
Race, n (%)
White 342 (81.4) 344 (82.9)
Asian 75 (17.9) 68 (16.4)
Black 0 (0.0) 1 (0.2)
Other 3 (0.7) 2 (0.5)
Age [years], mean (SD) 40.0 (16.1) 40.4 (16.6)
BMI [kg/m2], mean (SD) 24.6 (3.8) 24.8 (4.0)
Type of traveller, n (%)
Tourist 354 (84.3) 360 (86.7)
Business person 24 (5.7) 18 (4.3)
Student 26 (6.2) 21 (5.1)
Visiting friends/relatives 16 (3.8) 16 (3.9)
Country of residencea, n (%)
UK 136 (32.4) 141 (34.0)
Japan 35 (8.3) 37 (8.9)
Russia 38 (9.0) 30 (7.2)
Israel 22 (5.2) 33 (8.0)
Germany 23 (5.5) 31 (7.5)
France 21 (5.0) 14 (3.4)
South Korea 17 (4.0) 18 (4.3)
Spain 14 (3.3) 20 (4.8)
Duration (mean (SD)) between
Arrival at country and first
symptoms, days
12.4 (6.9) 12.0 (6.5)
n = 420 n = 415
First symptoms and
randomization, h
28.8 (15.0) 28.4 (14.5)
n = 419 n = 414
Number unformed stools during 24 h prior
to randomization, mean (SD)
5.5 (1.8) 5.4 (1.8)
n = 420 n = 415
Patients (n (%)) with 420 (100.0) 415 (100.0)
Maximum severity ‘mild’b 0 (0.0) 1 (0.2)
Maximum severity ‘moderate’b 328 (78.1) 329 (79.3)
Maximum severity ‘severe’b 92 (21.9) 85 (20.5)
Macroscopic stool findings at baseline,
n (%)
Presence of blood and/or mucus 127 (30.2) 119 (28.7)
aOnly countries listed if number of patients was at least 3% of the ITT population.
bGrading of severity: mild: not severe enough to change patient activity level; moderate:
caused a change in the patient’s daily activities; severe: rendered the patient disabled or he/
she had to stay in bed due to the gastrointestinal symptom.
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Discussion
Even if there is a decreasing trend in the incidence rate of TD,1
TD at many destinations remains the most frequent health prob-
lem abroad in rapidly increasing numbers of travellers.27,28
Only few among these profit of a decreased risk associated with
previous exposure to enteric pathogens in low-income coun-
tries.29 Particularly in this journal, there is an ongoing argumen-
tation on the indications and limitations of antimicrobial
therapy against TD30,31 despite the fact that a graded expert
panel report has been published just a few years ago.6 This
report does not only present a novel agent against TD, but also
responding to a recent request on priorities towards travel-
related research,32 it offers a first piece of evidence that not all
antimicrobials are equal with respect to increasing the risk for
multiresistant enteropathogens. Not only in the domain of vac-
cine preventable diseases do we need regular updates,33 in
future such data should become available also with respect to
pathogen resistance associated with TD and TD therapy.
This study demonstrated the efficacy of the oral multi-matrix
formulation of the broad-spectrum, poorly absorbed antibiotic
Rifamycin SV-MMX
®
(RIF-MMX) for the oral treatment of
non-dysenteric TD to be non-inferior to the systemic antibiotic
ciprofloxacin which until recently has been the antimicrobial of
choice for the treatment of TD. Non-inferiority was shown in
terms of the primary efficacy variable median TLUS. In this
study, TLUS was defined as the interval in hours between the
first dose of study drug and the last unformed stool (watery or
soft) passed, after which clinical cure was declared. In other
words, TLUS was defined as the time between the first dose of
the study drug and the last unformed stool before the end of the
clinical cure period. This is the most conservative way for deter-
mination of TLUS as it points to the end of the clinical cure peri-
od, i.e. a time the patient has overcome TD. This is in contrast
to the TLUS definition of other trials in the field of TD, which
defined TLUS as the time between the first dose of study drug
and the last unformed stool before the start of the clinical cure
period, which points to a time a patient starts to overcome
TD.16,21,34 We also analyzed the data using this TLUS definition
(modified TLUS), but also found no difference. Nevertheless,
the definition of TLUS affects the outcome quite strongly, with
a TLUS difference of 10.5 h and 5.8 h for the PP analysis of
RIF-MMX and ciprofloxacin groups, respectively, making the
definition of TLUS an important factor when comparing trials.
Interestingly, the obtained median in the modified TLUS results
resembled those from earlier trials with rifaximin.16
Interestingly, subgroup analysis clearly showed that median
TLUS was the shorter the earlier antibiotic treatment was
started after the onset of symptoms, suggesting that early ther-
apy of TD should be recommended at least in those patients
who need a rapid cure to assure their travel plans.
TLUS varies depending on where the study has been con-
ducted, as shown in this study by differing median TLUS in
patients recruited in India and Latin America (Table 3B). Thus,
comparison of TLUS between treatment groups within one
study is considered more meaningful than a comparison across
different studies.
In a previous clinical study, RIF-MMX showed a numeric-
ally, but due to the low number not statistically significant high-
er efficacy compared with placebo against potentially invasive
pathogens.21 Despite the trend of being more effective against
invasive bacteria compared with placebo, treatment with RIF-
MMX resulted in the current study into a statistically significant
longer TLUS compared with the ciprofloxacin group. However,
considering the low number of patients in this subgroup analysis
(n = 22 vs. 23), one has to interpret this result carefully. In
Table 2. Baseline pathogen detection (ITT population)
Rifamycin SV-MMX® Ciprofloxacin
(N = 420) (N = 415)
n (%) n (%)
Patients with at least one pathogen
at baseline
266 (63.3) 254 (61.2)
Diarrheagenic E. coli groupa 159 (37.9) 158 (38.1)
ETEC heat stable toxin 142 (33.8) 138 (33.3)
ETEC heat labile toxin 16 (3.8) 11 (2.7)
ETEC heat stable/labile toxin 17 (4.0) 9 (2.2)
EAEC 112 (26.7) 98 (23.6)
Potentially invasive/non-bacterial
groupb
107 (25.5) 96 (23.1)
Shigella spp. 9 (2.1) 8 (1.9)
Salmonella spp. 7 (1.7) 12 (2.9)
Campylobacter jejuni 20 (4.8) 26 (6.3)
Aeromonas spp. 8 (1.9) 9 (2.2)
Plesiomonas spp. 4 (1.0) 3 (0.7)
Vibrio spp. 0 (0.0) 0 (0.0)
Norovirus 11 (2.6) 12 (2.9)
Giardia lamblia 48 (11.4) 35 (8.4)
Cryptosporidium parvum 14 (3.3) 6 (1.4)
Entamoeba histolytica 1 (0.2) 3 (0.7)
Pathogen-negative groupc 152 (36.2) 158 (38.1)
aPositive for at least one of the following tests: enterotoxigenic E. coli (ETEC heat stable
toxin, heat labile toxin or heat stable/heat labile toxin) or enteroaggregative E. coli without
any positive result for pathogens of the invasive/non-bacterial group.
bPositive for at least one of the following pathogens: Shigella spp., Salmonella spp.,
Campylobacter jejuni, Aeromonas spp., Plesiomonas spp., Vibrio, Norovirus, Giardia lam-
blia, Cryptosporidium parvum or Entamoeba histolytica.
cPatients without positive detection of an enteric pathogen.
Table 3A. Primary endpoint (TLUS)
TLUS [h]
Rifamycin SV-MMX® Ciprofloxacin One-sided P-value (for non-inferiority)
n Median IQR n Median IQR
PP 384 42.8 21.3, 66.5 383 36.8 20.4, 65.5 0.0035
ITT 420 44.3 21.5, 68.2 415 40.3 20.5, 67.0 0.0011
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contrast, subgroup analysis of the TLUS by patients with and
without presence of blood and/or mucus in the macroscopic
stool analysis, indicative of at least slight intestinal mucosa dam-
age, revealed no difference in efficacy between the luminal act-
ing Rifamycin SV-MMX and the systemic ciprofloxacin.
RIF-MMX showed a similar antimicrobial activity as cipro-
floxacin against a broad range of pathogens involved in TD.
The rates of pathogen eradication were not different between
both treatment groups. This is in contrast to rifaximin, which
had statistically significantly lower eradication rates than cipro-
floxacin.16 As RIF-MMX targets the distal small bowel and
colon, the study further showed that these regions are not only
important reservoirs for the common bacterial pathogens associated
TD, but also represent valid targets for topical antibiotic therapy.
Figure 2. Kaplan–Meier plot of time to last unformed stool (TLUS) during the first 5 days after randomization (ITT population).
Table 3B. Subgroup analysis of primary endpoint (TLUS) (ITT population)
TLUS [h]
Rifamycin SV-MMX
®
Ciprofloxacin Comparison
N = 420 N = 415
n Median n Median Hazard ratio Log Rank test
[IQR] [IQR] [95% CI]
Region
India 405 45.0 [21.5, 69.0] 400 41.0 [21.1, 67.1] 0.965 [0.830, 1.121] P = 0.6367
Latin America 15 28.8 [18.4, 50.2] 15 29.5 [16.6, 49.3] 1.017 [0.470, 2.197] P = 0.9664
Pathogen statusa
Diarrheag. E. coli group 159 44.8 [23.0, 67.3] 158 42.3 [21.7, 65.0] 0.915 [0.722, 1.160] P = 0.4644
Pot. invasive bacteria group 22 56.2 [32.0, 120.0] 23 35.3 [18.0, 47.0] 0.370 [0.187, 0.732] P = 0.0031
Protozoa group 18 24.3 [15.3, 47.9] 9 35.0 [21.3, 44.8] 1.085 [0.458, 2.568] P = 0.8528
Norovirus group 6 40.8 [32.5, 48.2] 4 45.2 [43.4, 82.8] 2.067 [0.505, 8.462] P = 0.3030
Pathogen-negative group 152 43.0 [21.5, 68.4] 158 44.0 [22.8, 71.3] 1.164 [0.913, 1.484] P = 0.2207
Onset of symptoms to baseline visit
0 to <24 h 201 27.5 [19.2, 47.9] 192 27.7 [19.4, 48.5] 1.006 [0.819, 1.236] P = 0.9526
24 to <48 h 149 50.2 [26.1, 75.5] 163 44.1 [21.5, 80.3] 0.977 [0.761, 1.255] P = 0.8573
48–72 h 69 65.4 [48.3, 120.0] 58 64.6 [48.0, 79.6] 0.856 [0.573, 1.278] P = 0.4465
>72 h 0 – 1 76.5 [76.5, 76.5] –
Macroscopic stool findings
Presence of blood and/or mucus 127 48.2 [22.8, 69.2] 119 47.0 [26.0, 65.0] 0.902 [0.690, 1.180] P = 0.4528
No findings 293 40.5 [21.3, 67.3] 296 33.5 [20.3, 68.5] 0.983 [0.825, 1.173] P = 0.8523
aDiarrheag. E. coli group: includes patients with E. coli and no concurrent invasive pathogens. Pot. invasive bacteria group: positive for at least Shigella spp., Campylobacter jejuni,
Salmonella spp., Yersinia enterocolitica, Aeromonas spp., Plesiomonas spp. or Vibrio spp. and no other analyzed enteric pathogens. Protozoa group: positive for at least Giardia lamblia,
Cryptosporidium parvum or Entamoeba histolytica and no other analyzed enteric pathogens. Norovirus group: positive for norovirus and no other analyzed enteric pathogens.
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Although eradication rates were lower for both groups compared
with previous trials,16,21 it is difficult to draw clinical conclusions
as there seems a lack of correlation between eradication and clinical
outcome.35 In addition, it has to be taken into account that rifamy-
cin SV also has remarkable anti-inflammatory and immunomodula-
tory properties, particularly through the PXR receptor and NFkB
signalling pathway (Caridad Rosette, personal communication),
independent of its bactericidal activity.36–38 These in vitro activities
were superior when compared with rifaximin tested in parallel in
the same assays. Additionally, rifamycin SV appeared to be less
cytotoxic.37
Increases in MIC50 and MIC90 at Visit 3 became apparent
for rifamycin in the RIF-MMX group and for ciprofloxacin in
the Ciprofloxacin group. However, the increased MICs for
Rifamycin are still largely below the high intraluminal and fae-
cal concentrations of RIF-MMX.20 Also, the high MICs for
Campylobacter have to be seen in this context. In contrast,
fluoroquinolone resistance has expanded from Campylobacter-
Table 3C. Secondary endpoints (Clinical Cure Rate, Treatment Failure Rate and Requirement of Rescue Therapy) (ITT population)
Number (%) of patients
Rifamycin SV-MMX
®
Ciprofloxacin χ2 test
(N = 420) (N = 415) P-value
Clinical cure rate 357 (85.0) 352 (84.8) 0.942
Treatment failure rate 62 (14.8) 63 (15.2) 0.865
Requirement of rescue therapy 11 (2.6) 4 (1.0) 0.072
Figure 3. (A) Number of unformed stools per day during the first 5 days after randomization. (B) Percentage of patients with complete resolution of
clinical symptoms of enteric infection per day.
Table 4. Microbiological eradication rate
Rifamycin SV-MMX® Ciprofloxacin χ2 test
(N = 420) (N = 415)
n/N′ % n/N′ % P-value
All patients 131/266 49.2 126/254 49.6 0.935
Diarrheagenic E. coli group 77/159 48.4 80/158 50.6 0.695
ETEC-ST 65/142 45.8 69/138 50.0 0.479
ETEC-LT 9/16 56.3 3/11 27.3 0.137
ETEC-ST/LT 11/17 64.7 6/9 66.7 0.920
EAEC 67/112 59.8 66/98 67.3 0.259
Potentially invasive/non-bacterial group 54/107 50.5 46/96 47.9 0.717
Shigella spp. 6/9 66.7 7/8 87.5 0.312
Salmonella spp. 7/7 100.0 10/12 83.3 0.253
Campylobacter jejuni 17/20 85.0 19/26 73.1 0.331
Aeromonas spp. 5/8 62.5 8/9 88.9 0.200
Plesiomonas spp. 3/4 75.0 3/3 100.0 0.350
Norovirus 8/11 72.7 6/12 50.0 0.265
Giardia lamblia 27/48 56.3 20/35 57.1 0.935
Cryptosporidium parvum 13/14 92.9 5/6 83.3 0.515
Entamoeba histolytica 1/1 100.0 3/3 100.0
Note: n = number of patients with at least one isolate at baseline and no isolate at Visit 3, N′ = number of patients with at least one isolate at baseline.
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Table 5. Rifamycin SV and Ciprofloxacin MIC50/90 for bacterial isolates before and after treatment
Rifamycin SV-MMX® (N = 420) Ciprofloxacin (N = 415)
Visit 1 Visit 3 Visit 1 Visit 3
n MIC50/90 [μg/ml] n MIC50/90 [μg/ml] n MIC50/90 [μg/ml] n MIC50/90 [μg/ml]
EAEC Ciprofloxacin 112 0.03/16 22 0.01/8 98 0.06/16 24 0.01/64
Rifamycin SV 112 16/64 22 16/256 98 16/64 24 16/64
ETEC-LT Ciprofloxacin 16 0.06/16 6 0.02/0.25 11 0.13/16 7 1024/1024
Rifamycin SV 16 24/64 6 384/512 11 32/32 7 32/64
ETEC-ST Ciprofloxacin 142 0.13/32 60 0.09/32 138 0.09/32 57 0.13/64
Rifamycin SV 142 16/64 60 16/1024 138 16/64 57 16/32
ETEC-ST/LT Ciprofloxacin 17 0.06/0.25 6 0.14/16 9 0.13/16 3 16/1024
Rifamycin SV 17 16/64 6 264/1024 9 16/32 3 64/64
Aeromonas spp. Ciprofloxacin 8 0.06/0.25 2 0.31/0.50 9 0.25/2 −/−
Rifamycin SV 8 4/8 2 8/8 9 8/64 −/−
Campylobacter jejuni Ciprofloxacin 20 128/1024 3 8/1024 26 128/512 7 128/1024
Rifamycin SV 20 128/1024 3 1024/1024 26 64/1024 7 64/128
Plesiomonas spp. Ciprofloxacin 4 0.13/0.13 1 0.01/0.01 3 0.13/0.25 −/−
Rifamycin SV 4 3/4 1 256/256 3 4/4 −/−
Shigella spp. Ciprofloxacin 9 2/4 1 4/4 8 1.50/4 1 4/4
Rifamycin SV 9 16/16 1 64/64 8 16/64 1 32/32
Salmonella spp. Ciprofloxacin 7 0.01/0.02 −/− 12 0.01/0.13 −/−
Rifamycin SV 7 32/128 −/− 12 32/128 −/−
Table 6. ESBL-E.coli colonization before and after treatment
A) ESBL-E. coli by treatment group before and after treatment
Visit 1 Visit 3 P-valueb
Positive for ESBL-E. coli P-valuea Positive for ESBL-E. coli P-valuea
n/N′ % 95% CI n/N′ % 95% CI
Rifamycin SV-MMX
®
55/345 15.9 12.2, 20.2 0.5931 54/347 15.6 11.9, 19.8 0.0758 1.000 (N = 313)
Ciprofloxacin 48/338 14.2 10.7, 18.4 72/342 21.1 16.9, 25.8 0.0319 (N = 306)
aFisher’s exact test (Rifamycin SV-MMX
®
vs. ciprofloxacin).
bMcNemar’s test (Visit 1 vs. Visit 3). Only patients with a positive or negative result for ESBL-E at Visit 1 and Visit 3 were considered.
Note: N′ = number of patients with a positive or negative result for ESBL-E at Visit 1, N′ = number of patients with a positive or negative result for
ESBL-E at Visit 3.
B) ESBL-E. coli by treatment group for Visit 3, results at Visit 1 negative
Visit 3
Positive for ESBL-E.coli 95% CI P-value Value Odds ratio P-value
n/N′ % 95% CI
Rifamycin SV-MMX
®
27/263 10.3 6.9, 14.6 0.0221 1.84 1.10, 3.07 0.0197
Ciprofloxacin 45/259 17.4 13.0, 22.6
Note: N′ = number of patients with a negative result for ESBL-E at Visit 1.
C) ESBL-E. coli by treatment group for Visit 3, result at Visit 1 positive
Visit 3
Positive for ESBL-E. coli 95% CI P-value*
n/N′ %
Rifamycin SV-MMX
®
23/50 46.0 31.8, 60.7 1.000
Ciprofloxacin 21/47 44.7 30.2, 59.9
*Fisher’s exact test (Rifamycin SV-MMX
®
vs. ciprofloxacin).
Note: N′ = number of patients with a positive result for ESBL-E at Visit 1 and with a positive or negative result for ESBL-E at Visit 3.
9Journal of Travel Medicine
D
ow
nloaded from
 https://academ
ic.oup.com
/jtm
/article-abstract/25/1/tay116/5193265 by U
niversity of Zurich user on 22 February 2019
associated cases in Southeast Asia to widespread occurrence,
and increases among other common bacterial enteropathogens
including ETEC, EAEC, Shigella and non-typhoidal Salmonella.8,39,40
In this short-term study, however, no development of cross-resistance
was observed for either antibiotic.
ESBL-E. coli carriage and acquisition in the context of travel
and TD has been reported in recent years by studies from many
European countries.9,10,41–44 Travel to Asia, in particular South
Asia, and TD have been consistently found to be associated with
the highest risk for carriage and acquisition of ESBL-E. coli in all
studies. Use of antibiotics, and particularly of ciprofloxacin is
reported to be an independent risk factor for ESBL-E. coli acquisi-
tion9,10,44,45 and this has been confirmed by this trial. The clinical
relevance of these findings is enhanced by the fact that co-
resistance of ESBL-E. coli to other non-beta-lactam systemic anti-
biotics including fluoroquinolones (ciprofloxacin), cefotaxime,
TMP-SMX, gentamicin and cotrimoxazole is common and ESBL-
E. coli co-resistance to ciprofloxacin was found in ~51–53% of
isolates.10,44,46 In contrast, RIF-MMX did not increase EBSL-E.
coli carriage rate and did not promote new acquisition of ESBL-E.
coli. Furthermore, resistance of rifamycin is usually encoded chro-
mosomally and not on plasmids making horizontal gene transfer
and co-selection far less likely to occur.47–49
Rifamycin SV-MMX
®
at a dose of 800mg/day and cipro-
floxacin at a dose of 1000mg/day were safe and well-tolerated
during this short-term study. However, fluoroquinolones were
recently associated with disabling and potentially permanent
side effects of the tendons, muscles, joints, nerves and central
nervous system occasionally even after just a single dose and
various of these AEs can occur together in the same patient.13,14
These serious AEs were not detected with ciprofloxacin in this
study as they are uncommon. But the FDA released a Boxed
Warning, FDA’s strongest warning, for fluoroquinolones and
has advised restricted use of these antibiotics in certain uncom-
plicated infections considering that associated serious side
effects generally outweigh the benefits.11,12 Therefore, current
guidelines for the treatment of moderate to severe TD recom-
mend as systemic antibiotic now primarily azithromycin.6,7
However, increasing resistance is reported also for this anti-
microbial agent40,50 and systemic side effects may occur, albeit
rarely, such as sustained ventricular tachycardia in patients with
prolonged QTc.51 In contrast, poorly absorbed antibiotics not
only do not cause systemic side effects, but they also contribute
to reserve systemic antimicrobials to cure more severe infections
than TD. Therefore, RIF-MMX offers an advantage, which may
be particularly beneficial in subjects with co-morbidities and co-
medications.
In conclusion, RIF-MMX is a safe and effective non-
absorbable antibiotic to treat TD. Compared with systemic anti-
biotics, it has the advantage of not causing any systemic AEs. In
addition, it does not lead to an increased acquisition of ESBL-E.
coli while this is a relevant problem with ciprofloxacin. Thus,
this novel multi-matrix formulation of the broad-spectrum,
poorly absorbed antibiotic Rifamycin SV may be considered as
a first-line treatment for afebrile, non-dysenteric TD.
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